Product Description
Navitoclax is a BCL-XL/BCL-2 inhibitor that is being investigated to treat myelofibrosis. (Sourced from: https://www.abbvie.com/our-science/pipeline/navitoclax.html)
Mechanisms of Action: BCL2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Netherlands, New Zealand, Poland, Puerto Rico, Russia, Serbia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 12
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myelofibrosis
Phase 2: Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Phase 1: Acute Myeloid Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Myeloproliferative Disorders|Oncology Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05564650 |
22P.205 | P1 |
Active, not recruiting |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2024-05-03 |
50% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT05054465 |
ITALLI001 | P2 |
Not yet recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2025-08-01 |
2022-08-02 |
Primary Endpoints|Treatments |
|
NCT00788684 |
M10-166 | P1 |
Completed |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2025-02-07 |
2% |
2025-02-21 |
Primary Endpoints |
jRCT2080224824 |
jRCT2080224824 | P1 |
Completed |
Oncology Unspecified |
2024-09-08 |
|||
NCT04468984 |
TRANSFORM-2 | P3 |
Active, not recruiting |
Myelofibrosis |
2025-01-29 |
43% |
2025-04-26 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments |
NCT04041050 |
M19-753 | P1 |
Active, not recruiting |
Myeloproliferative Disorders |
2026-12-31 |
12% |
2025-02-15 |
Primary Endpoints |
NCT04472598 |
TRANSFORM-1 | P3 |
Completed |
Myelofibrosis |
2023-04-13 |
29% |
2025-02-22 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2023-507274-40-00 |
M19-753 | P1 |
Active, not recruiting |
Myelofibrosis |
2025-06-03 |
2025-05-02 |
Treatments |
|
NCT05455294 |
NCT05455294 | P1 |
Active, not recruiting |
Acute Myeloid Leukemia|Myelofibrosis|Myeloproliferative Disorders|Myelodysplastic Syndrome |
2024-04-17 |
50% |
2026-01-29 |
Primary Completion Date|Primary Endpoints|Treatments |
JapicCTI-194907 |
JapicCTI-194907 | P1 |
Active |
Oncology Unspecified |
2021-07-21 |
|||
2023-507276-53-00 |
M16-109 | P2 |
Completed |
Myelofibrosis |
2025-01-28 |
2025-05-02 |
Treatments |
|
NCT05192889 |
RAVEN | P2 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia |
2024-06-13 |
2% |
2024-11-27 |
Primary Endpoints |